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Microglial cells are crucial players in the pathological process of neurodegenerative
diseases, such as Alzheimer’s disease (AD). Microglial response in AD has been
principally studied in relation to amyloid-beta pathology but, comparatively, little is known
about inflammatory processes associated to tau pathology. In the hippocampus of
AD patients, where tau pathology is more prominent than amyloid-beta pathology,
a microglial degenerative process has been reported. In this work, we have directly
compared the microglial response in two different transgenic tau mouse models:
ThyTau22 and P301S. Surprisingly, these two models showed important differences
in the microglial profile and tau pathology. Where ThyTau22 hippocampus manifested
mild microglial activation, P301S mice exhibited a strong microglial response in parallel
with high phospho-tau accumulation. This differential phospho-tau expression could
account for the different microglial response in these two tau strains. However, soluble
(S1) fractions from ThyTau22 hippocampus presented relatively high content of soluble
phospho-tau (AT8-positive) and were highly toxic for microglial cells in vitro, whereas
the correspondent S1 fractions from P301S mice displayed low soluble phospho-
tau levels and were not toxic for microglial cells. Therefore, not only the expression
levels but the aggregation of phospho-tau should differ between both models. In fact,
most of tau forms in the P301S mice were aggregated and, in consequence, forming
insoluble tau species. We conclude that different factors as tau mutations, accumulation,
phosphorylation, and/or aggregation could account for the distinct microglial responses
observed in these two tau models. For this reason, deciphering the molecular nature of
toxic tau species for microglial cells might be a promising therapeutic approach in order
to restore the deficient immunological protection observed in AD hippocampus.
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INTRODUCTION
Alzheimer’s disease (AD), the most common cause of dementia
in the elderly, is pathologically characterized by the presence
of extracellular amyloid-beta (Abeta) plaques and intraneuronal
neurofibrillary tangles (NFTs) of highly phosphorylated tau
protein. Besides these two types of protein lesions, AD pathology
includes loss of synapses and selective neuronal cell death, along
with a chronic inflammatory response manifested by activated
microglia and astrocytes (for recent review Heppner et al.,
2015; Calsolaro and Edison, 2016; Ransohoff, 2016; Cuello,
2017). Microglial cells control the immune response in the
brain. Any insult that disrupts brain homeostasis is rapidly
detected by microglia, that become activated manifesting some
typical features as migration to the injury site, morphological
alterations, and changes in the gene expression profile (Hanisch
and Kettenmann, 2007; Wolf et al., 2017; Li and Barres, 2018).
The role of microglia in AD has been mainly studied in relation
to the amyloid pathology in both patients and animal models
(Jimenez et al., 2008; Prokop et al., 2013; Serrano-Pozo et al.,
2013; Guillot-Sestier et al., 2015; Sarlus and Heneka, 2017;
Hansen et al., 2018). However, microglial cells have also been
implicated in tau pathology during AD pathogenesis (for review,
Laurent et al., 2018).
The involvement of microglia as crucial players in the
progression of AD has recently been estimated (Calsolaro
and Edison, 2016; Ransohoff, 2016; Sarlus and Heneka, 2017).
Microglia seem to have an active and biphasic role on the AD
pathology, promoting at early stages the clearance of Abeta
deposits (Condello et al., 2015) and, at late stages, mediating
the loss of synapses (Wu et al., 2015; Spangenberg and Green,
2017), the exacerbation of the Abeta and tau pathologies (Xiang
et al., 2016; Leyns and Holtzman, 2017) and the secretion of
reactive oxygen species and inflammatory cytokines (Colonna
and Butovsky, 2017). Therefore, it remains doubtful if activated
microglia have a protective and/or detrimental effect in the
progression of AD pathology. Thus, a therapeutic possibility for
AD, targeting microglia, requires a fully understanding and a
better characterization.
Broad single-cell RNA sequencing (RNA-seq) analysis
in the 5XFAD model of AD identified a new and singular
disease-associated microglia (DAM) associated to amyloid
plaques (Keren-Shaul et al., 2017). These ‘DAM’ microglia are
molecularly characterized by expressing typical microglial
markers, such as Iba1, Cst3, and Hexb, coupled with
downregulation of “homeostatic” microglial genes (P2ry12,
Cx3cr1, CD33, and Tmem119) (Butovsky et al., 2014). DAM
cells further display upregulation of several genes identified as
AD risk factors, such as Apoe, Ctsd, Lpl, Tyrobp, and Trem2
(Lambert et al., 2013). Interestingly, DAM phenotype has also
been identified in other amyloidogenic AD mouse models
(Krasemann et al., 2017; Ofengeim et al., 2017; Mrdjen et al.,
2018), in tauopathy models (Leyns and Holtzman, 2017;
Friedman et al., 2018) and in other neurodegenerative diseases,
such as amyotrophic lateral sclerosis (Spiller et al., 2018) or
multiple sclerosis (Krasemann et al., 2017), as well as in aging
(Mrdjen et al., 2018; Olah et al., 2018). Nevertheless, the
mechanisms that regulate the microglia phenotype in disease are
not known.
Aging or genetic susceptibility may lead to impaired
microglia function (Streit et al., 2009, 2014). TREM2 has
been shown to have proliferative and pro-survival functions
in microglia (Otero et al., 2009; Ulland et al., 2017). It has
recently been demonstrated that the TREM2-APOE pathway
induces a microglia phenotypic switch from a homeostatic to
neurodegenerative profile (Krasemann et al., 2017). In this sense,
several mutations in TREM2 (such as R47H TREM2) produce an
increased risk for late-onset AD (Yeh et al., 2016) and impair the
microglial signals involved in survival, proliferation, chemotaxis,
and phagocytosis (Jay et al., 2017; Ulrich et al., 2017; Yeh et al.,
2017). Moreover, deficiencies in TREM2 are also associated with
rare hereditary neurodegenerative diseases (Paloneva et al., 2002;
Chitu et al., 2016). In both diseases, microglial response and,
more relevant, microglial survival seems to be compromised
(Konno et al., 2014; Tada et al., 2016).
Opposite to the strong microglial activation in amyloidogenic
mice, we have recently demonstrated a significant microglial
degenerative process in the hippocampus of AD patients
(Sanchez-Mejias et al., 2016; Gutierrez and Vitorica, 2018;
Navarro et al., 2018), a brain region with a more prominent tau
pathology than Abeta accumulation. We have also confirmed
that soluble phospho-tau was, at least in part, responsible for
this degenerative process. In the present study, we analyzed the
hippocampal microglial response in the context of tau pathology.
For this purpose, we compared two different transgenic mouse
models, ThyTau22 and P301S. While the hippocampus of
ThyTau22 animals manifested attenuated microglial activation
similar to AD patients, there was a clear microglial response in
the P301S model, reflecting remarkable differences in the innate
immune response to tau pathology.
MATERIALS AND METHODS
Mouse Models
Animal experiments were performed in accordance with the
Spanish and the European Union regulations (RD53/2013
and 2010/63/UE) and approved by the Animal Research
Committees from the Universities of Seville and Malaga
(Spain). For this study, 9–18 month-old APP751sl, 2–4
and 9–12 month-old ThyTau22 (commercialized by Sanofi),
and 2–4 and 9–12 month-old P301S (Jackson Laboratory)
transgenic animals, and age-matched wild-type mice (C57BL/6)
were used (males and female where used indifferently). The
APP mice over-expressed the human APP751 carrying the
Swedish (KM670/671NL) and London (V717I) mutations. The
ThyTau22 mice expressed human 4-repeat tau with G272V
and P301S mutations under a Thy1.2 promotor. The P301S
mice expressed human 4-repeat 1 N-terminal insert tau with
P301S mutation driven by the mouse prion protein (Prnp)
promoter (B6;C3-Tg(Prnp-MAPT∗P301S)PS19Vle/J). Mice were
anesthetized (sodium pentobarbital, 60 mg/kg) and processed as
described (Jimenez et al., 2008; Sanchez-Varo et al., 2012; Torres
et al., 2012).
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Antibodies
The following primary antibodies were used: anti-phospho-tau
AT100 (pSer212/Thr214, #MN1060, Thermo Fisher Scientific),
AT8 (MpSer202/Thr205, #MN1020, Thermo Fisher Scientific),
AT180 (Thr231, #MN1040, Thermo Fisher Scientific); anti-
total tau (Tau46, #4019S, Cell Signaling Technology and
Tau12 #MAB2241, Millipore); anti-b-actin (#A5316, Sigma-
Aldrich), anti-CD45 (IBL−3/16, Bio−Rad), Anti-Iba1 (#019-
19741, Wako Pure Chemical Industries), Anti−CD68 (#125212,
Abcam), anti-caspase 3 (#9661 Cell Signaling Technology), anti-
caspase 8 (#9429, Cell Signaling), anti-caspase 9 (#9507, Cell
Signaling). As secondary antibodies, we used HRP anti-mouse
(#7076S, Cell Signaling) and HRP anti-rabbit (#7074S, Cell
Signaling).
Preparation of S1 Soluble Fractions
Soluble fractions (S1) from mice brain cortex were prepared
as described (Jimenez et al., 2014). Briefly, mouse tissue was
homogenized using Dounce’s homogenizer, in PBS containing
protease and phosphatase inhibitors (Roche). Homogenates were
ultracentrifuged at 4◦C for 60 min, at 100,000 × g (OptimaMAX
Preparative Ultracentrifuge, Beckman Coulter). Supernatants
(S1 fractions), which comprise both extracellular and cytosolic
proteins, were aliquoted and stored at -80◦C until further use.
The pellets (P1) were processed using two different protocols:
A) P1 were sonicated applying 8 pulses of 15 s each and
then centrifuged 27,000 × g 4◦C, 15 min. The supernatant
obtained (S1s) was aliquoted and stored at -80◦C until further
use; B) P1 were extracted in RIPA buffer (1% CHAPS, 1% Na-
deoxycholate, 0.2% SDS, 140 mM NaCl, 10 mM Tris–HCl, pH
7.4); ultracentrifuged and supernatants, S2 fractions (intracellular
particulate proteins), were stored. Pellets (P2) were re-extracted
in buffered-SDS (2% SDS in 20 mM Tris–HCl, pH 7.4, 140 mM
NaCl), centrifuged as above and supernatants, S3 (SDS releasable
proteins) were stored at−80◦C.
Sarkosyl-Insoluble Fraction Isolation
Sarkosyl-insoluble tau was isolated as described (Luo et al., 2015).
Mouse hippocampi were homogenized in “homogenization
buffer” (10 mM Tris, 0.8 M NaCl, 1 mM EGTA, 10%
sucrose, pH 7.4, plus protease and phosphatase inhibitors).
Homogenates were ultracentrifuged at 4◦C for 60 min, 5,000× g.
Then, supernatants were incubated for 2.5 h at 37◦C in
agitation with 1% Sarkosyl (Sigma-Aldrich) and 1% beta-
mercaptoethanol (Sigma-Aldrich) in “homogenization buffer”
followed by ultracentrifugation (4◦C, 30 min, 100,000 × g).
Supernatants constituted the Sarkosyl soluble fractions and
pellets were the Sarkosyl-insoluble fraction. This insoluble
fraction was rinsed twice and resuspended in TBS.
Total RNA and Protein Extraction
RNA and proteins were isolated from mouse hippocampal
tissue using TriPure Isolation Reagent (Roche). RNA was first
purified and quantified using NanoDrop 2000 spectrophotometer
(Thermo Fischer). Proteins were then isolated, resuspended in
4% SDS, 8M Urea, and quantified using Lowry’s method.
Retrotranscription and Quantitative
Real-Time RT-PCR
Retrotranscription (RT) of 4 µg of total RNA was performed
with the High-Capacity cDNA Reverse transcription Kit
(Applied Biosystems). For real-time qPCR, 40 ng of
cDNA were mixed with Eagle Taq Master Mix (Sigma)
and Taqman Gene Expression assay probes (Applied
Biosystems). The following genes were analyzed, CD45
(ref. Mm01293577_m1), CD68 (ref. Mm03047340_m1),
Clec7a (Mm01183349_m1), CX3CR1 (Mm02620111_s1),
GAPDH (ref. Mm99999915_g1), Iba1 (ref. Mm00479862_g1),
IGF-1(ref Mm00439560_m1), P2ry12 (ref. Mm01950543_s1),
and TMEM119 (ref. Mm00525305_m1). Quantitative
PCR reactions (qPCR) were done using an ABI Prism
7900HT (Applied Biosystems). Results were expressed
using the comparative double-delta Ct method (2-11Ct).
1Ct values represent GAPDH normalized expression
levels.
Western Blots
Western blots were performed as previously described (Jimenez
et al., 2008). To analyze the different forms of Tau, protein
samples were loaded onto 4–20% SDS-Tris–Glycine-PAGE (Bio-
Rad). For the rest of the studied proteins, we used 12%
SDS-Tris–Glycine-PAGE. In all cases, proteins were transferred
to nitrocellulose membranes (Optitran, GE Healthcare Life
Sciences). Membranes were blocked using 2% low-fat milk in
TPBS (0.1% Tween-20, 137 mM NaCl, 2.7 mM KCl, 10 mM
phosphatebuffer, pH 7.4) and incubated overnight, at 4◦C,
with the appropriate primary antibody. Anti-mouse or anti-
rabbit horseradish-peroxidase-conjugated secondary antibodies
were used in each case at a dilution of 1/10.000. The blots
were developed using the Pierce ECL 2 Western Blotting
Substrate detection method (0.5 pg, lower limit sensitivity;
ThermoScientific). The images were obtained and further
analyzed with ChemiDocTM Touch Imaging System (Bio-Rad).
Immunohistochemistry
Fixed (4% paraformaldehyde) free-floating coronal brain sections
(40 µm thickness) from 9 month-old ThyTau22 and P301S mice
were assayed. After antigen retrieval (80◦C for 20 min in 50 mM
citrate buffer, pH 6.0), endogenous peroxidase was inhibited
(3% H2O2/10% methanol in PBS, pH 7.4 for 20 min) and
non-specific staining was avoided using 5% goat serum (Sigma-
Aldrich) in PBS. Sections were incubated with the primary
antibody (overnight at room temperature) followed by the
corresponding biotinylated secondary antibody (1:500 dilution,
1 h at room temperature, Vector Laboratories), streptavidin-
conjugated horseradish peroxidase (1:2000, 90 min, Sigma-
Aldrich), and visualized with 0.05% 3-3-diaminobenzidine
tetrahydrochloride (DAB, Sigma-Aldrich) and 0.01% hydrogen
peroxide in PBS. The specificity of the immune reactions was
controlled by omitting the primary antisera. Sections were
examined under a Nikon Eclipse 80i microscope and images were
acquired with a Nikon DS-5M digital camera using the ACT-2U
imaging software (Nikon Corporation).
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Cell Cultures
BV2 microglial cells were grown (37◦C and 5% CO2) in RPMI
1640, 2 mM glutamine, 10% (v/v) fetal bovine serum, plus
penicillin/streptomycin (all from Biowest). For experiments of
BV2 treatment with S1 soluble fractions, BV2 cells (15.000
cells/cm2) were serum deprived and treated with staurosporine
1uM (#S6942, Sigma) or S1 fractions (0.1µg/µl) for 3, 6, and 12 h.
When inhibiting caspases, 40 µM z-VAD-FMK (#V116, Sigma)
were added 30 min before S1 treatment.
Flow Cytometry Analysis of Cell Viability
The viability of BV2 cells was assessed using the apoptosis
detection kit Annexin V-FITC (Immunostep) following
the manufacturer’s specifications and was analyzed using a
FACS Canto II flow cytometer (BD Services, San Jose, CA,
United States).
Statistical Analysis
Data were expressed as the mean ± SD (GraphPad). Mean
values were compared using ANOVA followed by Tukey’s test
(more than two groups) or two-tailed t-test (for two group
comparisons). The significance was set at 95% of confidence.
RESULTS
Distinct Microglial Responses in the
Hippocampus of Mutant Transgenic Tau
Mice
We have previously reported the existence of a different
microglial response between Abeta and Tau-based mouse models
(Sanchez-Mejias et al., 2016). In fact, Abeta models, such
as APP or APP/PS1 transgenic mice, presented clear and
strong microglial activation, as determined by gene expression
or immunohistochemistry, whereas the tested Tau model
(ThyTau22) displayed low microglial activation (Sanchez-Mejias
et al., 2016; Navarro et al., 2018). In order to ascertain the
limited microglial response in Tau-based models, we have directly
compared the expression of different microglial genes in the
hippocampus of two Tau transgenic mice: ThyTau22 and P301S
mouse models. Furthermore, we have also included an APP-
model as positive control.
First, we evaluated, by qPCR, the expression of microglial
genes identified as DAM (disease associated microglia) program.
As expected (Figure 1A), the expression of microglial activation
markers (such as CD45, CD68, TREM2, Clec7a, and IGF-1)
FIGURE 1 | (A,B) Microglial DAM (A) and homeostatic (B) gene expression (qPCR) in ThyTau22 (n = 4–8/age) and P301S (n = 5–9/age) mice. Expression levels,
normalized using GAPDH, were referred to WT mice [9 months-old WT (n = 4)]. APP mice (9–18 months, n = 4–7) were also included as positive control. ∗p < 0.05.
Significance was analyzed by ANOVA followed by Tukey multiple comparison test. (C) Representative CD45 (c1–c6), Iba-1 (c7–c9) and CD68 (c10–c12)
-immunostained hippocampal sections from 9 month-old WT (c1, c4, c7, c10), ThyTau22 (c2, c5, c8, c11) and P301S (c3, c6, c9, c12) mice. DG, debate gyrus;
so, stratum oriens; sp, stratum pyramidale; sr, stratum radiatum. Scale bars, (c1–c3) 400 µm; (c4–c12) 100 µm; insets 20 µm.
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was significantly increased in the APP model (as compared to
WT). Also, as previously reported (Sanchez-Mejias et al., 2016),
ThyTau22 model displayed a limited microglial response at both,
early (2–4 months) and advanced (9–12 months) ages. However,
unexpectedly, we did observe strong microglial activation in the
P301S model. In fact, the expression of all tested genes was even
higher than that observed in our APP-based model. This strong
response was restricted to 9–12 month-old P301S mice.
On the other hand, it has been reported that the microglial
activation was paralleled by a decrease in the expression of
the homeostatic genes (Keren-Shaul et al., 2017). Thus, we
have also determined the expression of some homeostatic genes
in the same animal cohorts. As shown, no differences were
found in P2ry12 or TMEM119 whereas a significant increase
was observed in CX3CR1 and Iba1 (Figure 1B). This increase
may be due to an increment in the number of microglia
cells, suggesting a possible proliferation of microglial cells upon
activation (Askew et al., 2017; Baglietto-Vargas et al., 2017; Tay
et al., 2017).
The microglial response in these two different Tau-models was
also assessed by immunohistochemistry using CD45, Iba1, and
CD68 antibodies. As shown in Figure 1C, most of microglial cells
in the hippocampus of the P301S model were clearly positive
for the marker of activated microglia CD45 (Figures 1C,c3,c6).
In fact, the microglial cells from all hippocampal fields were
strongly immunopositive showing an activated morphotype
characterized by hypertrophic cell body and short processes.
However, in parallel experiments, the ThyTau22 mice barely
showed any CD45-positive cells (Figures 1C,c2,c5). As expected,
Iba1-positive microglia was normally present in both models
(Figures 1C,c8,c9) and the morphological changes, related to
activation, were easily detected in the P301S but hardly in
ThyTau22 microglial cells, which mostly displayed a resting
phenotype similar to WT mice (Figures 1C,c7). Finally,
an additional marker specific for activated microglia with
phagocytic activity, CD68 (Figures 1C, c10–12), exhibited a
immunostaining pattern similar to CD45, confirming the above
findings.
Therefore, these results demonstrated the existence of a strong
microgliosis in Tau-based models. Nonetheless, this microglial
response was clearly different depending on each Tau transgenic
line.
P301S Mice Showed Stronger Tau
Pathology Than ThyTau22 Mice
An increase in the microglial response could be due to a different
Tau expression and/or phosphorylation between these two
models. Thus, we next directly tested the accumulation of total
Tau in both models by western-blot using Tau46 (C-terminal) and
Tau12 (N-terminal) antibodies. As expected, significant higher
levels of total Tau were observed in P301S mice when compared
to ThyTau22 mice (see Figure 2A).
This different tau accumulation could also produce a different
phosphorylation pattern between both models. Therefore, we
indirectly tested this possible difference using three phospho-
specific monoclonal antibodies (AT8, AT100, and AT180), by
western-blot. As expected (see Figure 2B), we observed an
age-dependent increase in tau phosphorylation in both models.
As shown, young (2–4 months of age) ThyTau22 or P301S
mice displayed low (below the detection limits) phospho-tau
accumulation. However, at 9–12 months of age, both ThyTau22
and P301S mice showed a significant accumulation in phospho-
tau species, positive for all tested antibodies. In consonance with
the high Tau expression, P301S model presented higher phospho-
tau species, when compared with ThyTau22 mice (Figure 2B).
In addition, we verified the differences in tau phosphorylation
by immunohistochemistry. We compared AT8-inmunostained
sections from 9 month-old ThyTau22 and P301S mice. As shown
in Figure 2C, in both Tau models the accumulation of phospho-
tau, visualized by AT8 immunostaining, in the hippocampal
region was notably higher when compared to other adjacent brain
regions as cerebral cortex or thalamus (Figures 2C,c1,c5 rostral
levels; Figures 2C,c2,c6 caudal levels). AT8 immunolabeling
in the ThyTau22 hippocampus was associated with principal
cells depicting neuronal perikarya and proximal dendrites in
the CA1 region and dentate gyrus (Figures 2C,c3 and detail
in Figures 2C,c4). Noteworthy, P301S hippocampus showed
stronger neuropile phospho-tau immunostaining than ThyTau22
hippocampus. The stratum oriens and stratum radiatum of
CA1 region displayed a widespread labeling, and numerous
principal cell perikarya from stratum pyramidale appeared
immunopositive (Figures 2C,c7 and detail in Figures 2C,c8).
Thus, these results suggest that the P301S model exhibits a
higher tau pathology compared to the ThyTau22 model, which
could explain the higher microgliosis reported.
Soluble Phospho-Tau From P301S and
ThyTau22 Mice Exerts Different Toxic
Effect Upon Microglial cells
We have recently reported the toxic effect of soluble phospho-
tau fraction on microglial cells in vitro (Sanchez-Mejias et al.,
2016). Therefore, a higher expression and accumulation of
phospho-tau species should produce higher microglial toxicity.
Thus, we directly compared the toxic effect, on BV2 microglial
cells, of soluble phospho-tau isolated from either 12 month-old
ThyTau22 or P301S cerebral cortex. These soluble fractions (S1)
comprised both extracellular and cytosolic proteins.
First, we tested the effect of S1 fractions from ThyTau22
mice after 3, 6, and 12 h of treatment. As shown (Figure 3A)
the S1 from 12 month-old ThyTau22 mice produced a clear
and significant reduction in the number of viable BV2 cells, as
compared to 2 month-old ThyTau22 mice (see also Sanchez-
Mejias et al., 2016). After 12 h of treatment with S1 fractions,
a significant low percentage of cells (13.7 ± 10.4%) remained
viable. This pro-apoptotic effect was also ascertained by testing
caspase activation. It is widely accepted that an increment in
the cleavage of caspase 3 (17 kDa fragment) could reflect the
apoptosis activation process. On the other hand, the cleavage
of caspase 8 (43 kDa) or caspase 9 (38 kDa) was specific for
the extrinsic or the intrinsic pathway, respectively. As shown in
Figures 3B,b1,b2, S1 fractions derived from ThyTau22 models
produced a clear and significant activation of caspases 8 and 3
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FIGURE 2 | (A) Total tau (T46 upper panel and T12 lower panel) protein levels in 9 month-old P301S and ThyTau22 mice (n = 4–6). (B) Phospho-tau (AT8, AT100,
AT180 antibodies) protein levels in P301S and ThyTau22 mice (n = 6). (b1) Representative western-blots. (b2) WB quantification, ∗p < 0.05, significance was
analyzed by t-test between young and aged mice in each model and between aged P301S and ThyTau22 mice. (C) Representative AT8-immunostained
hippocampal sections from 9 month-old ThyTau22 (c1–c4) and P301S (c5–c8) mice. so, stratum oriens; sp, stratum pyramidale; sr, stratum radiatum. Scale bars,
(c1, c2, c5, c6) 500 µm, (c3, c7) 100 µm, (c4, c8) 20 µm.
and a non-significant increase of caspase 9, after 3 and 6 h of
treatment. These results suggested that microglial cell death after
treatment with soluble phospho-tau, was probably due to the
activation of apoptotic pathways.
To support this finding, we also assessed the protective effect
of a pan-caspase inhibitor (z-VAD-FMK) over the toxicity of
12-month old Thytau22 S1 fractions. As expected, in presence
of z-VAD-FMK, the microglial viability was preserved (from
16 ± 8.8% to 83 ± 17.1% of viable cells after 6 h of treatment;
n = 3).
Additionally, in order to evaluate if this microglial death
was due to a depletion of ATP reservoirs, due to strong cell
activation, ATP levels were measured in BV2 cells treated with
S1 fractions from 12 month-old ThyTau22 mice. No changes
were observed in ATP levels (see Figures 3B,b3), which may
suggest that cell apoptosis is not trigger by a depletion of ATP
pool.
On the other hand, we also tested whether similar soluble
(S1) fractions isolated from P301S were also toxic for BV2
cells. Surprisingly (see Figures 3A,a1,a2), no toxicity was
observed even after 12 h of treatment. In order to evaluate if
this difference was due to a lower toxic dose of the soluble
fractions, BV2 cells were treated with higher concentrations of
S1 fractions (0.2 and 0.4 ug/ul) from 12 month-old P301S mice.
As shown in Figures 3A,a2, even after a four-fold increase
in the S1 dosage, no decrease in microglial viability could be
observed.
Different Tau Aggregation in Tau-Based
Mouse Models
So far, our results demonstrated the different microglial response
and toxicity between two Tau-based tg models. The strong
microglial response observed in P301S, as compared with
ThyTau22, could be a direct consequence of the higher Tau
accumulation, both total and phosphorylated, observed in this
particular model. However, this fact could not explain the non-
toxic versus toxic effect of soluble phospho-tau on the microglial
viability. Therefore, it is also possible the existence of a different
aggregation pattern between both models.
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FIGURE 3 | (A) Soluble fractions (S1) from aged ThyTau22 mice were toxic for BV2 microglial cells whereas S1 from aged P301S mice had no effect in the viability of
microglial cells. (a1) Representative Annexin V/propidium iodide (PI) double staining of BV2 cells treated with S1 fractions at 0.1 ug/ul for 12 h. (a2) Quantitative
analysis of cell viability after exposure to S1 fractions. Data is shown as the mean + SD (n = 3–5). ∗p < 0.05. Significance was determined by ANOVA and Tukey
post-hoc test. (B) Caspase activation following microglial treatment with soluble phospho-tau from 12 month-old ThyTau22 mice. (b1) Representative western blots
showing caspase 3, 8, and 9 activation in BV2 cells treated with S1 from aged ThyTau22 mice (0.1 ug/ul). B-actin (low panel) was used as the loading control.(b2)
The relative abundance of cleaved caspases was determined by densitometry analysis. Data were normalized by positive control (staurosporine 1 µM), and
significance was determined by ANOVA and Tukey post-hoc test (n = 3).(b3) No differences in ATP levels were observed in BV2 cells treated with S1 fractions from
12 month-old ThyTau22 mice (0.1 ug/ul). Data is shown as the mean + SD (n = 3).
In order to explore this possibility, we first quantified the
phospho-tau forms in the soluble fractions from P301S and
ThyTau22 mice. As shown in Figure 4A, a significant higher
level of soluble (S1 fractions) phospho-tau forms (AT8 positive)
was observed in ThyTau22 compared to P301S model. This
finding, although unexpected, may explain the non-toxic effect
on microglia cells of S1 fractions from 12 month-old P301S
mice.
As reported above, there was a higher tau
expression/accumulation in the P301S model than in the
Thytau22 mouse model. Therefore, we hypothesized that
most of tau forms in P301S mice could be aggregated and, in
consequence, in form of insoluble tau species. Thus, we next
evaluated the phospho-tau accumulation in different fractions
isolated from mouse cortex (see Methods). Briefly, the S1
fractions comprise both extracellular and cytosolic proteins
whereas the S3 fractions correspond to SDS releasable proteins.
In consonance with our hypothesis, most (if not all) tau species
were preferentially concentrated in the soluble fractions in
ThyTau22 model whereas an appreciable fraction of tau was
found in the SDS-releasable pool in P301S (see Figure 4B).
Therefore, the lower toxicity and the lower soluble phospho-tau
observed in P301S model could just reflect a higher aggregation
status of the different phosphorylated Tau forms. In fact,
aggregated phospho-tau (Sarkosyl-resistant fraction) extracted
from either P301S model (showing a 96.8 ± 0.43% of BV2 viable
cells after 12 h of treatment with Sarkosyl-resistant fraction,
n = 3) or even from AD patients (Sanchez-Mejias et al., 2016)
produced no microglial toxicity.
Finally, we evaluated whether the mechanical disaggregation
of the phospho-tau fractions from P301S mice (see Methods)
produced soluble and toxic phospho-tau species. To this
effect, we sonicated and ultracentrifuge the pellet obtained
after S1 fractions extraction (P1). The supernatants constituted
the sonication-dependent soluble fractions (S1s). As expected,
after sonication, soluble AT8- and AT100-positive bands
were clearly visible in the S1s fractions (see Figure 4C).
This AT8/AT100 positive band was absent in the non-
sonicated S1 soluble fractions and was also absent at early
ages, before tau phosphorylation. Therefore, sonication of
the aggregated phospho-tau produced soluble phospho-tau
forms.
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FIGURE 4 | (A) Higher phospho-tau accumulation (AT8) in S1 fractions from 9 to 12 month-old ThyTau22 mice compared to paired P301S mice. The relative
abundance of phospho-tau was determined by densitometry analysis. Tau46 (low panel) was used as the loading control. Data is shown as the mean + SD
(n = 3–6). ∗p < 0.05. Significance was analyzed by t-test between young and aged mice in each model and between aged P301S and ThyTau22 mice.
(B) Representative western-blot of total tau accumulation (T46) in S1 and S3 fractions from WT, ThyTau22 and P301S mice. (C) Representative western-blot of
phospho-tau (AT8 and AT100) in S1 and S1s fractions from P301S mice. (D) Quantitative analysis of BV2 viability (determined by flow cytometry) after 12 h of S1s
treatment at 0.1 ug/ul. Data is shown as the mean + SD (n = 3).
Since our previous data indicated that soluble phospho-tau
was toxic for microglia in vitro (Sanchez-Mejias et al., 2016),
we then tested whether these S1s fractions were also toxic for
BV2 cells. Unexpectedly, we did not observe any decrease in BV2
viability after 12 h of treatment with S1s fractions from 9 to
12 month-old P301S mice (see Figure 4D).
DISCUSSION
In this work we have compared the hippocampal microglial
response in two different mutant transgenic tau mouse models,
ThyTau22 and P301S. Surprisingly, our results demonstrate
important differences between these two models of tau pathology.
Contrary to the low microglial activation manifested in the
hippocampus of ThyTau22 mice, the P301S mice display a
strong microgliosis, even stronger than that observed in an
amyloidogenic APP-model. In contrast, we also demonstrated
that brain soluble S1 fractions isolated from ThyTau22 mice
are highly toxic for microglial cells in vitro, whereas equivalent
S1 fractions from P301S mice produce no toxicity. These
discrepancies in the microglial response to tau pathology
between both models may reflect differences in accumulation,
phosphorylation and/or tau aggregation.
Numerous studies suggest that the exclusive presence of
tau pathology induces microglial activation. In fact, microglial
activation has been linked to tau deposition in different
human tauopathies, such as AD (Sheffield et al., 2000),
progressive supranuclear palsy (Ishizawa and Dickson, 2001)
and corticobasal degeneration (Gerhard et al., 2004; Henkel
et al., 2004), as well as in transgenic rats expressing human
non-mutated truncated tau (Zilka et al., 2009; Stozicka et al.,
2010), and in different transgenic mice with overexpression
of the human mutated tau protein. In agreement with our
results, a robust neuroinflammatory response characterized by
microgliosis has been described in the mouse model expressing
human P301S mutated tau protein under the control of
the Thy1 promotor (Bellucci et al., 2004) and in patients
with frontotemporal dementia carrying the P301S mutation
(Bellucci et al., 2011). Additionally, the PS19 line, which is
another transgenic mouse model carrying the P301S mutation,
showed microgliosis and synaptic pathology in hippocampus
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preceding neurofibrillary tangle formation and neuronal loss
(Yoshiyama et al., 2007). More recently, it has been stated that
the age-dependent human mutated tau expression in the rTg4510
mouse model leads to tau-dependent inflammatory changes (Wes
et al., 2014). In fact, the genetic removal of Tau seems to prevent
the microglial activation and the associated neurodegeneration
(Maphis et al., 2015a,b).
Moreover, microglial activation has been implicated in all
the different pathological steps associated with tau-patholohy
such as phosphorylation, aggregation, propagation and synaptic
alteration (for review, see Laurent et al., 2018). It has recently
been demonstrated that microglial cells phagocyte aggregated tau
and secret exosomes, which are transmissible to neurons. In this
sense, microglia are believed to play a key role in tau spreading
(Asai et al., 2015).
However, as we and others have also reported (Sanchez-Mejias
et al., 2016; Laurent et al., 2017) there is a mild microglial
activation in some Tau-based models and even in AD samples.
Present results also confirm the moderate microglial response in
ThyTau22 model and the strong microglial activation in P301S
mice. Similar differences between Tau models have been also
reported using single cell RNA-seq (Friedman et al., 2018). The
reasons that explain the distinct microglial responses are not
known. The mechanisms underlying tau-mediated microglial
activation has not yet been fully identified. Multiple membrane
receptors and intracellular signal transduction pathways have
been implicated, highlighting the essential role of TREM2
receptor (Takahashi et al., 2005; Melchior et al., 2010; Kleinberger
et al., 2014). What is more, microglia from P301S mice showed
higher TREM2 mRNA levels while the pathology is progressing,
and silencing of TREM2 exacerbated tau pathology and spatial
learning deficits in P301S mice (Jiang et al., 2015).
On the other hand, characterization of tau species involved
in microglial activation is an open question. Morales et al.
(2013) studied in vitro the effect of tau aggregates over
microglial cells and concluded that oligomeric or filamentous tau
forms, but not monomeric, triggered microglial activation. More
recently, Nilson et al. (2017) demonstrated that tau oligomers
take part in the feed-forward mechanisms, which leads to
chronic neuroinflammation. They verified that T22-positive tau
oligomers co-localized with microglia in frontotemporal lobar
dementia and AD subjects, which may suggest the engulfment
of tau oligomers by microglia and its consequent activation.
According with these statements, and using the T22 antibody, we
have confirmed, by dot-blot, the presence of oligomeric forms of
tau in the soluble fraction S1 of the P301S hippocampus, but not
in that of the ThyTau22 (data not shown), which could justify the
remarkable differences in the microglial activation between these
two tau models.
Additionally, the severity of tau pathology may be a key point
in microglial activation. It has been reported that misfolded
truncated tau protein is able to activate microglia at the
concentration of 100 nM (Kovac et al., 2011). In support of
this notion, our results demonstrated that the amount of total
and phospho-tau species were much higher in aged P301S than
in aged ThyTau22 mice. Moreover, the P301S hippocampus
manifested a stronger and more extensive distribution of
phospho-tau immunostaining than ThyTau22 mice. Similar
results were found by Chen et al. (2016) in the bigenic line
5xFAD/ThyTau22. Therefore, the different microglial response
could simply reflect the differences in tau expression between
different models, as it is the case with APP-based models.
Beside the scarce microglial activation produced in the
ThyTau22 transgenic model, we have previously reported a
significant decrease in the hippocampal area covered by the
individual microglia cells in 9–12 month-old animals. This
microglial pathology could resemble that one present in
the human Braak V–VI hippocampus, where most of the
parenchymal space of the hilar region was not protected by
microglial cells (Sanchez-Mejias et al., 2016). In the same sense,
Streit et al. (2009) showed that neuronal structures positive for
tau are associated with dystrophic (pathological) rather than
activated microglial cells. We have also established that soluble
phospho-tau was implicated in this degenerative microglial
process in the AD hippocampus. Corroborating this fact, our
in vitro results in this work demonstrated that the soluble (S1)
fractions isolated from 12-month-old ThyTau22 mice, but not
those from old P301S animals, were toxic for BV2 cells. More
important, we demonstrated that the S1 fractions from aged
ThyTau22 mice, compared to that from P301S mice, exhibited a
much higher phospho-tau accumulation (AT8), which seems to
be responsible for this microglial degeneration. In fact, our results
confirmed that, at least extrinsic apoptotic pathway is mediating
microglial death, as demonstrated by the significant activation of
caspases 3 and 8 in BV2 cells after treatment with S1 from aged
ThyTau22 mice.
Ours results established, for the first time, that in ThyTau22
model most tau species were preferentially concentrated in
the soluble fractions whereas in P301S mice an appreciable
fraction of tau seems to be aggregated in form of insoluble
tau species. We have also detected that the insoluble fraction
from 9 to 12 month-old P301S mice accumulated a higher
content in phospho-tau species than the S1 fraction. However,
and unexpectedly, these phospho-tau species, when solubilized,
did not produced any toxic effect for microglia cells in vitro, in
contrast to the degenerative effect of soluble phospho-tau from
ThyTau22 mice and AD patients hippocampi. As these soluble
fractions should contain a mixture of tau species, we cannot
establish which form(s) of phospho-tau is directly involved
in the toxic effect upon microglial cells. Nevertheless, it is
important to highlight that not all phospho-tau species from
AD samples are toxic for microglial cells, as demonstrated
when treating BV2 cells with Sarkosyl-insoluble phospho-
tau (Sanchez-Mejias et al., 2016). It is widely known that
intracellular paired helical filaments, which are the basis for the
formation of neurofibrillary tangles, content Sarkosyl-insoluble
phospho-tau. Consequently, as it has already been stated, tangle
formation may be considered as a protection mechanism which
could prevent neuronal (Santacruz et al., 2005) and microglial
toxicity.
In conclusion, our results show that tau pathology effect
upon microglia differs enormously among transgenic tau
models.A diversity of toxic tau species differing in morphology,
solubility, and disease-relevant properties can be reported
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inresponse to different factors including tau mutations,
isoform composition, and post-translational modification(Guo
et al., 2017). These differing forms of phospho-tau might
contribute to the distinct microglial responses observed in
the two tauopathies murine models studied in this work.
Consequently, not all mutant transgenic tau models reproduce
the human AD-associated hippocampal microglial pathology.
The molecular nature/conformation of the toxic tau species for
microglial cells is an important issue to be addressed in future
research.
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